12.5 C
New York

Tag: Corp

Totality Corp CEO explains why India continues to be largely untapped for NFTs

Regardless of rating as one of many highest adopters of cryptocurrency amongst rising markets, nearly all of the Indian market is but to embrace...

Top News

Terran Orbital stock cleared for trading on NYSE

Tag Template - News Hub PRO

Shares in satellite manufacturer Terran Orbital Corp. were cleared to begin trading Monday on the New York Stock Exchange under the ticker symbol LLAP, Live Long and Prosper

The post Terran Orbital stock cleared for trading on NYSE appeared first on SpaceNews.

Wynn Resorts New CEO Sees Non-Gaming Investments in Macau, Elsewhere as Pivotal

Craig Billings took the helm as chief executive officer of Wynn Resorts (NASDAQ:WYNN) at the start of February. He’s already looking to shake things up by evaluating non-gaming amenities in Macau and dialing back expenditures on the company’s online sportsbook operation. In a normal operating environment, which hasn’t been seen in Macau since 2019, the […]

The post Wynn Resorts New CEO Sees Non-Gaming Investments in Macau, Elsewhere as Pivotal appeared first on Casino.org.

Item 9 Labs’ Orion 710 Live Resin Pods Named Best Indica and Sativa Cannabis Vape at 2022 Spring ERRL Cup

PHOENIX — Item 9 Labs, the award-winning, premium cannabis brand from Item 9 Labs Corp. (OTCQX: INLB), announced today it took home four podium placements at the Spring ERRL Cup, held March […]

Here’s Which VC-Backed Companies Are Going Public Via SPAC In 2022 (So Far)

Tag Template - News Hub PROLast year was a banner year for special-purpose acquisition companies, but so far it’s unclear if this year will pan out to be nearly as active for the SPAC market. 

LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) Committed to Driving Bitcoin Adoption via Lightning Network Offering; Network Tripled Capacity in 2021

The Lightning Network provides instant payment transfers/settlement times, scalability, low costs/fees, and works across blockchain with the same cryptographic hash function The Network’s capacity grew from 1,089 BTC to 3,479 BTC in 12 months LQwD’s active public nodes on the Lightning Network include France, England, Singapore, Sweden, Italy, Indonesia, Germany, Ireland, and the U.S. and … Continue reading "LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) Committed to Driving Bitcoin Adoption via Lightning Network Offering; Network Tripled Capacity in 2021"

The post LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) Committed to Driving Bitcoin Adoption via Lightning Network Offering; Network Tripled Capacity in 2021 appeared first on CryptoCurrencyWire.

Flora Growth to Expand Physical Presence in Europe Through JustCBD Partnership with Greenyard

MIAMI & TORONTO–(BUSINESS WIRE)–Flora Growth Corp. (NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global ... Read More
Tag Template - News Hub PRO

Federal Appeals Court Affirms the Role of ‘Balance’ in Scheme for Extending Term of Pharmaceutical Patents

Federal Appeals Court Affirms the Role of ‘Balance’ in Scheme for Extending Term of Pharmaceutical Patents

Balance On 18 March 2022, the Full Court of the Federal Court of Australia issued decisions relating to term extensions of patents covering pharmaceutical products: Commissioner of Patents v Ono Pharmaceutical Co. Ltd [2022] FCAFC 39 (‘Ono’); and Merck Sharp & Dohme Corp. v Sandoz Pty Ltd [2022] FCAFC 40 (‘MSD’).  The two decisions have (at least) three things in common.  First, both were decided unanimously by a panel comprising Chief Justice Alsop and Justices Yates and Burley.  Second, both found against the patentee, with the court reversing the primary judge’s decision in Ono granting an extension of term, and confirming the primary judge’s decision in MSD nullifying a previously granted extension of term.  And, third, both referred to the principle set out in the objects clause (section 2A) of the Patents Act 1990 that ‘the patent system balances over time the interests of producers, owners and users of technology and the public’ (emphasis added).

The scheme for extending the term of pharmaceutical patents inherently involves a balancing act.  Its primary purpose is to ensure that patentees are not excessively disadvantaged by delays in securing regulatory approval to market patented products.  For example, if a drug is not approved for use until 10 years or more after a patent application is filed, the patentee may have less than half of the standard 20 year patent term remaining to compensate for its investment in discovery and development before becoming exposed to generic competition.  On the other hand, an extended period without competition necessarily exposes the wider public to higher costs of medical treatment.  In an effort to balance these competing interests, the relatively complex provisions of the Patents Act aim to ensure that a ‘typical’ pharmaceutical patentee benefits from up to 15 years of exclusivity, by granting extensions of the patent term of up to five years, i.e. to a maximum of 25 years from filing.  (A 2013 review of pharmaceuticals patents – which the government initially declined to release – found that 53% of such patents have an effective life of 15 years, while 89% have an effective life of over 10 years.)

The primary provisions of the Patents Act governing extensions of patent term are:

  1. section 70, which sets out the conditions that must be satisfied before a patentee can apply for an extension of the term of its patent;
  2. section 71, which sets time limits for filing of applications for extensions of term; and
  3. section 77, which specifies how the duration of an extension of term is to be calculated. 

In each of Ono and MSD, the patentee sought to obtain an advantage, or avoid disadvantage, by arguing for beneficial interpretations of the extension of term provisions.  In each case they failed.  And in both cases the Full Court upheld the principle that the purpose of the extension of term scheme is to balance the competing interests of the patentee of a pharmaceutical substance against the public interest in the unrestricted use of the pharmaceutical invention after expiry of the patent.  In Ono, in particular, the Full Court rejected the proposition that sections 70, 71, and 77 should be construed to achieve a commercial outcome for the patentee.  In MSD the Full Court again invoked the principle of ‘balance’ in declining to permit an extension of term based on a later Australian marketing approval, in circumstances where the patentee had already obtained the benefit of an ‘export only’ approval of a substance falling within its patent claims with an effective life of over 15 years.

The relevance of the Full Court’s focus on balancing of interests, and its references to the objects clause, could extend beyond these cases.  The three judges here are all among the five who recently heard the appeal in the Thaler ‘AI inventor’ case, in which the competing interests of developers and owners of ‘invention machines’, and of the broader public (who might not see the same benefit in granting patent monopolies on automatically-generated inventions), are potentially at stake.  It will be interesting to see whether they adopt a similar approach to weighing up the balance of interests in that case, also.

Read more »

RF Acquisition Corp. (RFACU) Prices $100M IPO


RF Acquisition Corp. announced the pricing of its $100 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “RFACU” Thursday, March 24.

The new SPAC intends to search globally for target companies within the Southeast Asian new economy sector or elsewhere. ...READ MORE

Marlena Haddad

Avista Public Acquisition Corp. II (AHPA) to Combine with Ligand Pharmaceuticals

Avista Public Acquisition Corp. II (NASDAQ:AHPA) has entered into a definitive agreement to acquire Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) to spin-off its antibody discovery business OmniAb, Inc. at a pre-money equity valuation of $850 million. The San-Diego based biopharmaceutical company is focused on developing technologies that help pharmaceutical companies discover medicine. Ligand’s OmniAb platform provides
Read More

To access this post, you must purchase a Monthly or Yearly SPACInsider Subscription, or log in if you're a member.

Marlena Haddad

Welsh Carson brings in veteran exec Jesse Hunter as latest operating partner

Healthcare and tech-focused private equity major Welsh, Carson, Anderson & Stowe has hired Centene Corp veteran Jesse Hunter as its latest operating partner.

The post Welsh Carson brings in veteran exec Jesse Hunter as latest operating partner first appeared on AltAssets Private Equity News.

Fusang delays security-token IPO amid market jitters

Tag Template - News Hub PRO Conflict in Ukraine takes a toll on Malaysian exchange’s $10 million IPO just a week before planned listing.

China launches military spy satellite

China launched a classified military remote sensing satellite March 17 on a Long March 4C rocket. The three-stage rocket placed the Yaogan 34-02 satellite into an orbit at an altitude of 680 miles.
Tag Template - News Hub PRO

Recent articles

spot_img